ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
DemeRx Receives MHRA Approval for DMX-1002 Study for Opioid Use Disorder americanpharmaceuticalreview
March 17, 2021DemeRx IB, an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... -
MHRA green light for DemeRx’s opioid use disorder trial pharmatimes
March 11, 2021The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD).
Pharma Sources Insight January 2025
